Mediobanca Vows to Boost Payouts to Fend Off Monte Paschi Bid
Mediobanca SpA plans to return €4.9 billion ($5.7 billion) to shareholders by 2028, as the Italian lender seeks to defend against a takeover bid from rival Banca Monte dei Paschi di Siena SpA.
The bank sees revenue growing to above €4.4 billion by 2028, at an annual rate of 6%, it said in a strategy update disclosed Friday. Net profit is seen rising to almost €2 billion over the same period.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Stifel Reports Y/Y Rise in Client & Fee-Based Assets for May 2025
Stifel Financial Corp. SF reported key operating results as of May 31, 2025, highlighting year-over-year increases in client and fee-based assets, despite volatility in equity markets. The company's total client assets increased 8% year over year and 3% from the prior month's level in May 2025, reaching $501.4 million. This is driven by market appreciation and the successful recruitment of financial advisors. Fee-based client assets rose 13% year over year and 4% sequentially in May to $199.1 million. Private Client Group's fee-based client assets were $173.6 million as of May 31, 2025, up 12% from the year-ago quarter and 5% from the previous month's level. Bank loans, net (including loans held for sale), were $21.2 million as of May 2025, up 7% year over year but down 2% sequentially. Client money market and insured product balances decreased 2% on a year-over-year basis and nearly 1% on a sequential basis in May due to a lower Smart rate balance, as the Sweep deposit balance also witnessed a slight decline. SF's May total client assets and fee-based assets increased, indicating strong growth in client engagement and portfolio value. Further, a rise in bank loans, net, implies a positive trend in lending activities and revenue growth from this segment. However, declining client money market and insured product balances suggest a decline in liquidity and possibly a negative market perception. In April, the investment banking activity was negatively affected by the market volatility. However, as the market stabilized, its momentum increased, and the investment banking pipeline strengthened throughout the quarter. Though IB revenue is expected to decrease in the second quarter of 2025, management remains cautiously optimistic for the full year 2025. In the past year, Stifel shares have risen 25.5% underperforming the industry's rise of 40.6%. Image Source: Zacks Investment Research Currently, SF carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. LPL Financial LPLA witnessed a rise in total brokerage and advisory assets in May 2025. The metric was $1.85 trillion, which grew 3.7% from the prior month and 26.5% year over year. LPLA reported a total client cash balance of $49.2 billion in May, down 5% from the prior month but up 10.6% from May 2024. Of the total balance, $33.4 billion was insured cash, $10.6 billion was deposit cash, and the remainder consisted of money-market sweep and client cash balances. Charles Schwab SCHW also released its monthly activity report for May 2025. The company's total client assets were $10.35 trillion, up 12.4% from May 2024 and 4.6% from April 2025. SCHW's Client assets receiving ongoing advisory services were $5.24 trillion, growing 12.6% from the year-ago period and 3.9% from the prior month. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Charles Schwab Corporation (SCHW) : Free Stock Analysis Report Stifel Financial Corporation (SF) : Free Stock Analysis Report LPL Financial Holdings Inc. (LPLA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
28 minutes ago
- Yahoo
The 5 Most Interesting Analyst Questions From Masimo's Q1 Earnings Call
Masimo's first quarter results were met with a significant negative market reaction, reflecting investor concern over new headwinds despite revenue and adjusted earnings surpassing Wall Street expectations. Management attributed the strong revenue growth primarily to solid demand across core healthcare offerings and the timing of a large tender contract, which temporarily boosted capital equipment sales. CEO Katie Szyman highlighted the company's operational improvements and the expansion of recurring consumable and service revenue, while also noting areas for improvement in commercial execution. CFO Micah Young pointed to meaningful operating margin expansion driven by last year's cost optimizations and a renewed focus on the core healthcare business. However, the company acknowledged that timing-related lumpiness in tender contracts led to lower consumables sales, with expectations that these trends will normalize in future quarters. Is now the time to buy MASI? Find out in our full research report (it's free). Revenue: $372 million vs analyst estimates of $367.9 million (9.5% year-on-year growth, 1.1% beat) Adjusted EPS: $1.36 vs analyst estimates of $1.22 (11.5% beat) Adjusted EBITDA: $123.8 million vs analyst estimates of $108.5 million (33.3% margin, 14.1% beat) Management lowered its full-year Adjusted EPS guidance to $4.98 at the midpoint, a 5.2% decrease Operating Margin: 21%, up from 15.6% in the same quarter last year Constant Currency Revenue rose 10.5% year on year (-12.5% in the same quarter last year) Market Capitalization: $9.04 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Frederick Wise (Stifel) asked about the impact of the large tender contract on future quarters. CFO Micah Young clarified the effect was timing-related and expects normalization in upcoming quarters. Vik Chopra (Wells Fargo) questioned whether tariffs would alter long-term margin goals. Young responded that underlying margins remain strong and mitigation plans are in place, but the ultimate impact depends on trade policy resolution. Jason Bednar (Piper Sandler) inquired about hospital capital spending trends and the effect of a recent IT incident. Young stated that recurring revenue is robust and the IT issue should not change guidance based on current information. Mike Matson (Needham) queried the rationale for prioritizing share repurchases over debt reduction following the Sound United sale. Young said capital allocation will depend on market conditions but buybacks are currently prioritized. Matt Taylor (Jefferies) sought clarification on margin expansion and the practical impact of tariff mitigation initiatives. Young emphasized ongoing investments and noted that the real benefit of mitigation actions may materialize toward year-end and into next year. Over the next few quarters, the StockStory team will be closely monitoring (1) the execution of tariff mitigation strategies and any relief from trade negotiations, (2) the effectiveness of the new regionally-focused sales force in driving cross-category product growth, and (3) the pace and impact of innovation in next-generation monitoring devices and algorithms. Additionally, updates on the deployment of Sound United sale proceeds and operational performance normalization after recent contract timing shifts will serve as key indicators of Masimo's ability to navigate current market challenges. Masimo currently trades at $164.49, up from $160.67 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Yahoo
28 minutes ago
- Yahoo
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about CRISPR Therapeutics AG (CRSP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. CRISPR Therapeutics currently has an average brokerage recommendation (ABR) of 1.88, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 27 brokerage firms. An ABR of 1.88 approximates between Strong Buy and Buy. Of the 27 recommendations that derive the current ABR, 15 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 55.6% and 3.7% of all recommendations. Check price target & stock forecast for CRISPR Therapeutics here>>> The ABR suggests buying CRISPR Therapeutics, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. Looking at the earnings estimate revisions for CRISPR Therapeutics, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at -$5.54. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for CRISPR Therapeutics. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for CRISPR Therapeutics. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
